Summit Therapeutics plc

BioNTech made its name and fortune with its Pfizer-partnered COVID-19 vaccine, Comirnaty, but this year could be a turning point in its bid to diversify and become a major oncology company as well. Th

Summit Therapeutics and its partner Akeso have a commanding lead in the VEGF x PD-(L)1 bispecific cancer immunotherapy field, but BioNTech is also focused on being a major contender. Several key clini

Summit Therapeutics and Pfizer have unveiled a collaboration which could help them compete with leaders in one of the most promising cancer fields, namely combinations of immunotherapy (IO) and antibo

Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by